Sardocor Cardiac Gene Therapy: First-Mover Positioning in Asia-Pacific, Zero Clinical Data to Validate It

Medera Expands Singapore Presence, Advances Cardiac Gene Therapies

Medera Inc. announced an expanded partnership with the National Heart Centre Singapore (NHCS), supported by Singapore’s Research, Innovation and Enterprise 2025 (RIE2025) framework. This collaboration aims to advance human mini-heart-based cardiac disease modeling, translational research, and non-animal drug discovery. Concurrently, Medera is establishing a Singapore laboratory and office to serve as an Asia-Pacific hub for its cardiac technology platform. The company is also progressing its cardiac gene therapy programs through its Sardocor subsidiary, including a randomized clinical trial for heart failure with reduced ejection fraction (HFrEF) currently underway in Singapore, believed to be the first of its kind in the region.

• Medera's expanded partnership with the National Heart Centre Singapore (NHCS), through its Novoheart subsidiary, focuses on developing and validating human-relevant cardiac disease models. These models are intended for drug discovery, cardiotoxicity assessment, therapeutic efficacy testing, and translational cardiovascular research, supported by Singapore’s RIE2025 framework.
• The establishment of a new laboratory and office in Singapore positions the city-state as a crucial Asia-Pacific hub for Medera's cardiac technology platform, translational research partnerships, and regional business development. This strategic expansion complements Medera's broader international footprint and its collaboration with IQVIA for global deployment of Novoheart’s human cardiac technology platforms.
• Medera is advancing its cardiac gene therapy programs via its therapeutic subsidiary, Sardocor, targeting heart failure. This includes a randomized clinical trial for heart failure with reduced ejection fraction (HFrEF) currently underway in Singapore, marking what is believed to be the first cardiac gene therapy clinical trial in the country. Medera also plans to expand its heart failure with preserved ejection fraction (HFpEF) program into its regional clinical development strategy.

Medera's Singapore Hub to Advance HFrEF Drug Discovery

Despite significant advances in guideline-directed medical therapy (GDMT), the management of HFrEF continues to face substantial real-world implementation gaps and clinical barriers that limit optimal patient outcomes.

• Underuse of GDMT in clinical practice: Early and rapid initiation of the 4 pillars of GDMT has been shown to significantly improve morbidity and mortality in HFrEF, yet GDMT remains significantly underused. Contributing factors include the lack of simplified, patient-profile-tailored treatment protocols, concerns regarding safety or tolerability of medications, and therapeutic inertia.

• Difficulty achieving target doses: Even in structured clinical settings, reaching goal doses across all GDMT classes is uncommon. In the COAPT trial, among patients with LVEF ≤40% who underwent systematic HF specialist-directed GDMT optimization, goal doses were achieved for beta-blockers in only 32.3% and for ACEIs/ARBs/ARNIs in only 10.2% of patients, with only 2.2% tolerating goal doses across all 3 GDMT classes. Hypotension and kidney dysfunction were the most common intolerances limiting titration.

• Logistical barriers to titration: Implementing swift initiation and titration of GDMT in practice remains a significant challenge for healthcare systems. Conventional approaches require frequent in-clinic assessment visits, contributing to delays in reaching optimal medical therapy (OMT).

• Uncertainty around ICD use in the contemporary GDMT era: The landmark studies underpinning current ICD recommendations for primary prevention of sudden cardiac death (SCD) in HFrEF preceded the 4 pillars of GDMT, prompting questions about the continued role of ICDs in current clinical practice given the impact of contemporary GDMT on outcomes.

• Unmet needs in advanced and end-stage HFrEF: As HF progresses, patients experience high symptom burden, recurrent hospitalizations, and poor quality of life. An increasing proportion of patients progresses to advanced stages and are ineligible for heart transplantation or mechanical circulatory support due to age, comorbidities, frailty, or limited social support, leaving significant unmet needs in this population.

Key Trial Designs and Endpoints in HFrEF Gene Therapy

Several landmark trials have shaped the evidence base for HFrEF pharmacotherapy, spanning diverse study designs, patient populations, and endpoint frameworks. The trials below reflect a range of interventions — from soluble guanylate cyclase stimulators and SGLT2 inhibitors to potassium binders and cardiac resynchronization — each evaluated against clinically meaningful composite and individual endpoints.

Navigating the Evolving HFrEF Treatment Landscape

The HFrEF treatment landscape has been substantially reshaped by the emergence of SGLT2 inhibitors as a foundational pillar of guideline-directed medical therapy (GDMT). The DAPA-HF and EMPEROR-Reduced trials established that dapagliflozin and empagliflozin, added to standard HF therapy, deliver clear clinical benefit in reducing the primary endpoint of CV mortality or HF hospitalization in HFrEF patients with or without type 2 diabetes — with HF hospitalization reductions of HR 0.70 (95% CI 0.59–0.83; ARR 3.7%) and HR 0.69 (95% CI 0.59–0.81; ARR 5.1%), respectively. A network meta-analysis comparing sacubitril/valsartan, vericiguat, and SGLT2 inhibitors across PARADIGM-HF, VICTORIA, DAPA-HF, EMPEROR-Reduced, and DECLARE-TIMI 58 ranked SGLT2 inhibitors as the most effective therapy overall, followed by sacubitril/valsartan and vericiguat, though the difference in risk of CV death or HF hospitalization between SGLT2 inhibitors and sacubitril/valsartan did not reach statistical significance (HR 0.92, 95% CI 0.81–1.05). Evidence has also extended to HFpEF (EF >40%) through the EMPEROR-Preserved and DELIVER trials, and to hospitalized acute HF patients through EMPULSE and DICTATE-AHF, broadening the therapeutic reach of this drug class considerably.

Alongside the consolidation of SGLT2 inhibitors, the field has moved toward earlier, more aggressive implementation of all four GDMT pillars — an angiotensin receptor-neprilysin inhibitor (ARNI), a beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. The STRONG-HF trial validated rapid up-titration strategies, demonstrating that early high-intensity GDMT implementation with structured follow-up significantly reduces 180-day mortality and readmissions. Evidence-based rapid sequencing proposals advocate initiating all four foundational treatments within 2–4 weeks, prioritising low starting doses across all classes over up-titration to target doses, given that the efficacy of each foundational therapy is independent of treatment with the other drugs. Despite this evidence base, real-world adoption remains uneven; Indian registry data, for instance, indicate that just one quarter of patients leave hospital with complete GDMT, and fewer than 5% receive ARNIs.

Novel mechanisms of action have also entered the HFrEF landscape. Omecamtiv mecarbil, a selective cardiac myosin activator, was evaluated in the GALACTIC-HF trial — a randomised, double-blind, placebo-controlled, event-driven outcomes trial enrolling more than 8,000 patients with LVEF ≤35%. The trial demonstrated a treatment effect for the primary endpoint of CV death or first HF event (HR: 0.92 [95% CI: 0.86–0.99]; P = 0.03), with the benefit consistent across age groups and particularly pronounced in patients with severe HF (LVEF ≤30%, NYHA class III/IV, HF hospitalisation within 6 months), where omecamtiv mecarbil significantly reduced the primary outcome in both patients <65 years (HR: 0.77 [95% CI: 0.64–0.92]) and those ≥65 years (HR: 0.83 [95% CI: 0.71–0.97]). Subsidiary analyses from GALACTIC-HF have further characterised prognostic factors in contemporary HFrEF populations, including the finding that hypermagnesaemia — present in 10.7% of outpatients — was associated with a higher incidence rate of the primary composite outcome (34.9 per 100 person-years, 95% CI 31.2–39.0) compared to normal magnesium concentrations, while abnormal magnesium levels were not associated with a higher risk of sudden death or ventricular tachyarrhythmias.

Medera's Dual Strategy: Advancing Cardiac Models and Gene Therapy

Medera Inc.'s latest announcement signals a bold, dual-pronged strategy to tackle cardiovascular disease, a leading cause of global mortality. By expanding its partnership with the National Heart Centre Singapore and establishing an Asia-Pacific hub, Medera is making a significant investment in human-centric preclinical research. This move leverages cutting-edge advancements in human induced pluripotent stem cell (hiPSC)-derived cardiac models, including engineered heart tissues (EHTs) and cardiac organ chips. These sophisticated platforms are designed to more accurately simulate human cardiac physiology and pathology, addressing a critical gap where traditional animal models often fall short in predicting drug efficacy and cardiotoxicity.

This focus on advanced in vitro models holds the promise of accelerating drug discovery, reducing the reliance on animal testing, and ultimately bringing more effective and safer therapies to patients faster. Studies indicate that these models can faithfully replicate physiological and pharmacological responses, offering a more predictive tool for screening compounds and modeling diseases like dilated cardiomyopathy. However, the full translational impact of these advanced models, from preclinical success to clinical approval, remains an area requiring ongoing validation.

Concurrently, Medera is pushing forward with its cardiac gene therapy programs for heart failure with reduced ejection fraction (HFrEF), a condition with persistent high hospitalization rates and mortality. While gene transfer for HFrEF has faced significant hurdles, with large trials like CUPID 2 failing to meet primary endpoints despite safety, Medera's commitment to a randomized clinical trial in Singapore highlights a determination to innovate in this challenging space. This high-risk, high-reward endeavor aims to unlock a potentially transformative treatment. Yet, the path is fraught with known challenges, including the need to demonstrate clear clinical efficacy, ensure long-term durability of gene expression, manage potential immunogenicity, and mitigate risks of liver toxicity, as seen in other gene therapy applications. Successfully navigating these scientific and clinical complexities will be crucial for Medera to realize its ambitious vision in cardiovascular medicine.